SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics has successfully integrated its recent acquisitions, including Bio-Tech Solutions and Dermatonics, bolstering its operations with a projected annual turnover increase to £6.3 million for FY25. Despite unexplained share price movements, the company remains on solid financial ground, with cash reserves expected to sustain operations until Summer 2026. This expansion, along with ongoing partnerships, positions SkinBioTherapeutics for significant growth in the skin health sector.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
